TABLE 1.
Subject demographic and HIV-related data for dose-escalation and relative bioavailability studies
| Characteristic | Dose-escalation study
|
Relative bio-availability of amprenavir (n = 18) | |
|---|---|---|---|
| Amprenavir (n = 12) | Placebo (n = 6) | ||
| No. of subjects | |||
| Male | 9 | 6 | 15 |
| Female | 3 | 0 | 3 |
| Race | |||
| White | 12 | 5 | 10 |
| Black | 0 | 0 | 7 |
| Other | 0 | 1 | 1 |
| Age (yr)a | 33 ± 6.7 | 29 ± 5.0 | 31.94 ± 5.21 |
| Wt (kg)a | 64 ± 9.6 | 73 ± 3.3 | 71.58 ± 8.55 |
| Ht (cm)a | 171 ± 9.5 | 179 ± 8.2 | 174.5 ± 6.69 |
| HIV infection status (no. of subjects) | |||
| Asymptomatic (CDC classification A) | 11 | 6 | 15 |
| Symptomatic (CDC classification B) | 0 | 0 | 3 |
| AIDS (CDC classi-fication C) | 1 | 0 | 0 |
| CD4+ count (cells/mm3)b | 392 ± 127.2 | 484 ± 202.5 | 387 ± 250 |
| CD8+ count (cells/mm3)b | 1,194 ± 683 | 699 ± 250.5 | 755.5 ± 269 |
a
Values are given as means ± standard deviations.
b
Values are given as medians ± standard deviations.